menu
    • menu
    [{"orgOrder":0,"company":"Numab Therapeutics","sponsor":"3SBio ","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Large molecule","year":"2020","type":"Series B Financing","leadProduct":"ND021","moa":"PD-L1","graph1":"Oncology","graph2":"IND Enabling","graph3":"Numab Therapeutics","amount2":0.02,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"","sponsorNew":"Numab Therapeutics \/ 3SBio ","highestDevelopmentStatusID":"5","companyTruncated":"Numab Therapeutics \/ 3SBio "},{"orgOrder":0,"company":"Numab Therapeutics","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Large molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Multi-specific antibody","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Numab Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Numab Therapeutics \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"2","companyTruncated":"Numab Therapeutics \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Numab Therapeutics","sponsor":"Kaken Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Large molecule","year":"2021","type":"Licensing Agreement","leadProduct":"NM26-2198","moa":"","graph1":"Dermatology","graph2":"Phase I","graph3":"Numab Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"","sponsorNew":"Numab Therapeutics \/ Kaken Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Numab Therapeutics \/ Kaken Pharmaceuticals"},{"orgOrder":0,"company":"Numab Therapeutics","sponsor":"Novo Holdings","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Large molecule","year":"2021","type":"Series C Financing","leadProduct":"NM21-1480","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Numab Therapeutics","amount2":0.11,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.11,"dosageForm":"","sponsorNew":"Numab Therapeutics \/ Novo Holdings","highestDevelopmentStatusID":"7","companyTruncated":"Numab Therapeutics \/ Novo Holdings"},{"orgOrder":0,"company":"Numab Therapeutics","sponsor":"Sunshine Guojian Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Large molecule","year":"2021","type":"Partnership","leadProduct":"ND021","moa":"4-1BB receptor","graph1":"Oncology","graph2":"Preclinical","graph3":"Numab Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Numab Therapeutics \/ Numab Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Numab Therapeutics \/ Numab Therapeutics"},{"orgOrder":0,"company":"Numab Therapeutics","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Large molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Antibody","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Numab Therapeutics","amount2":0.28000000000000003,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.28000000000000003,"dosageForm":"","sponsorNew":"Numab Therapeutics \/ Ono Pharmaceutical","highestDevelopmentStatusID":"3","companyTruncated":"Numab Therapeutics \/ Ono Pharmaceutical"},{"orgOrder":0,"company":"Numab Therapeutics","sponsor":"Kaken Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"NM26-2198","moa":"","graph1":"Dermatology","graph2":"Phase I","graph3":"Numab Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"","sponsorNew":"Numab Therapeutics \/ Kaken Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Numab Therapeutics \/ Kaken Pharmaceuticals"},{"orgOrder":0,"company":"Numab Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"NM26-2198","moa":"","graph1":"Dermatology","graph2":"Phase I","graph3":"Numab Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Numab Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Numab Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Numab Therapeutics","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Large molecule","year":"2024","type":"Collaboration","leadProduct":"NM49","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Numab Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Numab Therapeutics \/ Ono Pharmaceutical","highestDevelopmentStatusID":"4","companyTruncated":"Numab Therapeutics \/ Ono Pharmaceutical"},{"orgOrder":0,"company":"Numab Therapeutics","sponsor":"Johnson & Johnson","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Large molecule","year":"2024","type":"Acquisition","leadProduct":"NM26","moa":"","graph1":"Dermatology","graph2":"Phase I","graph3":"Numab Therapeutics","amount2":1.25,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":1.25,"dosageForm":"Injection","sponsorNew":"Numab Therapeutics \/ Johnson & Johnson","highestDevelopmentStatusID":"6","companyTruncated":"Numab Therapeutics \/ Johnson & Johnson"},{"orgOrder":0,"company":"Numab Therapeutics","sponsor":"Kaken Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Large molecule","year":"2024","type":"Collaboration","leadProduct":"ND081","moa":"","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Numab Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"Numab Therapeutics \/ Kaken Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Numab Therapeutics \/ Kaken Pharmaceuticals"},{"orgOrder":0,"company":"Numab Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"NM32-2668","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Numab Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Numab Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Numab Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Numab Therapeutics","sponsor":"Cormorant Asset Management","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Antibody","year":"2025","type":"Series C Financing","leadProduct":"NM26","moa":"IL-4R alpha\/IL-31","graph1":"Dermatology","graph2":"Phase I","graph3":"Numab Therapeutics","amount2":0.20000000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0.20000000000000001,"dosageForm":"Injection","sponsorNew":"Numab Therapeutics \/ Cormorant Asset Management","highestDevelopmentStatusID":"6","companyTruncated":"Numab Therapeutics \/ Cormorant Asset Management"}]

    Find Clinical Drug Pipeline Developments & Deals by Numab Therapeutics

    Menu

    Numab Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Numab Therapeutics

                            Switzerland arrow
                            ELCC
                            Not Confirmed

                            Numab Therapeutics

                            Switzerland arrow
                            ELCC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NM26

                            Therapeutic Area : Dermatology

                            Study Phase : Phase I

                            Sponsor : Cormorant Asset Management

                            Deal Size : $197.6 million

                            Deal Type : Series C Financing

                            DEALS_DEV arrow-down

                            Numab Extends Series C to CHF 180M With CHF 50M Oversubscribed Financing

                            Details : The Proceeds will be used to support the advancement of multiple first-in-class and best-in-class programs into clinical development, which includes NM26-2198 is being evaluated for atopic dermatitis.

                            Product Name : NM26-2198

                            Product Type : Antibody

                            Upfront Cash : Undisclosed

                            January 09, 2025

                            Lead Product(s) : NM26

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase I

                            Sponsor : Cormorant Asset Management

                            Deal Size : $197.6 million

                            Deal Type : Series C Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Numab Therapeutics

                            Switzerland arrow
                            ELCC
                            Not Confirmed

                            Numab Therapeutics

                            Switzerland arrow
                            ELCC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ND081

                            Therapeutic Area : Gastroenterology

                            Study Phase : Preclinical

                            Sponsor : Kaken Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Numab and Kaken Collaborate On ND081 for Inflammatory Bowel Disease

                            Details : The collaboration aims to develop ND081, a potential first-in-class multi-specific antibody for the treatment of inflammatory bowel disease (IBD).

                            Product Name : ND081

                            Product Type : Large molecule

                            Upfront Cash : $14.6 million

                            November 15, 2024

                            Lead Product(s) : ND081

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Preclinical

                            Sponsor : Kaken Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Numab Therapeutics

                            Switzerland arrow
                            ELCC
                            Not Confirmed

                            Numab Therapeutics

                            Switzerland arrow
                            ELCC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NM32-2668

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Numab Starts Phase 1 Study of NM32 in Solid Tumor Patients

                            Details : NM32 is a next generation tri-specific immuno-oncology drug targeting the ROR1 receptor & CD3. It is being evaluated for the treatment of solid tumors.

                            Product Name : NM32

                            Product Type : Large molecule

                            Upfront Cash : Not Applicable

                            October 30, 2024

                            Lead Product(s) : NM32-2668

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Numab Therapeutics

                            Switzerland arrow
                            ELCC
                            Not Confirmed

                            Numab Therapeutics

                            Switzerland arrow
                            ELCC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NM26

                            Therapeutic Area : Dermatology

                            Study Phase : Phase I

                            Sponsor : Johnson & Johnson

                            Deal Size : $1,250.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Johnson & Johnson Gains Rights to Clinical-Stage Bispecific Antibody for Atopic Dermatitis

                            Details : The agreement aims to acquire NM26, a Phase 2-ready investigational, first-in-class bispecific antibody targeting two clinically proven pathways in atopic dermatitis (AD).

                            Product Name : NM26-2198

                            Product Type : Large molecule

                            Upfront Cash : $1,250.0 million

                            May 28, 2024

                            Lead Product(s) : NM26

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase I

                            Sponsor : Johnson & Johnson

                            Deal Size : $1,250.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Numab Therapeutics

                            Switzerland arrow
                            ELCC
                            Not Confirmed

                            Numab Therapeutics

                            Switzerland arrow
                            ELCC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NM49

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Ono Pharmaceutical

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Numab and Ono Announce Collaboration Agreement for NM49 Cancer Treatment

                            Details : Ono obtained rights for NM49 from Numab for global development and commercialization. NM49 is a multi-specific antibody designed to activate tumor-associated macrophage phagocytosis for cancer.

                            Product Name : NM49

                            Product Type : Large molecule

                            Upfront Cash : Undisclosed

                            February 14, 2024

                            Lead Product(s) : NM49

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Ono Pharmaceutical

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Numab Therapeutics

                            Switzerland arrow
                            ELCC
                            Not Confirmed

                            Numab Therapeutics

                            Switzerland arrow
                            ELCC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NM26-2198

                            Therapeutic Area : Dermatology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Numab Therapeutics Announces First Patient Dosed in Phase 1 Multiple Ascending Dose (MAD) Study of NM26 for Mo...

                            Details : NM26/NM26-2198, a first-in-class bi-specific antibody for the treatment of moderate-to-severe atopic dermatitis (AD). MAD data expected to be reported in mid-2024; Single ascending dose (SAD) cohort in healthy volunteers remains ongoing.

                            Product Name : NM26

                            Product Type : Large molecule

                            Upfront Cash : Not Applicable

                            October 19, 2023

                            Lead Product(s) : NM26-2198

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Numab Therapeutics

                            Switzerland arrow
                            ELCC
                            Not Confirmed

                            Numab Therapeutics

                            Switzerland arrow
                            ELCC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NM26-2198

                            Therapeutic Area : Dermatology

                            Study Phase : Phase I

                            Sponsor : Kaken Pharmaceuticals

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Numab Therapeutics Announces First Subject Dosed in Phase 1 Clinical Study of NM26 Program

                            Details : NM26-2198 is a bi-specific antibody which targets IL-4Rα (type I and type II receptors) and IL-31 for the treatment of moderate-to-severe atopic dermatitis (AD).

                            Product Name : NM26-2198

                            Product Type : Large molecule

                            Upfront Cash : Not Applicable

                            May 15, 2023

                            Lead Product(s) : NM26-2198

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase I

                            Sponsor : Kaken Pharmaceuticals

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Numab Therapeutics

                            Switzerland arrow
                            ELCC
                            Not Confirmed

                            Numab Therapeutics

                            Switzerland arrow
                            ELCC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Antibody

                            Therapeutic Area : Oncology

                            Study Phase : Discovery Platform

                            Sponsor : Ono Pharmaceutical

                            Deal Size : $276.6 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Numab Therapeutics and Ono Pharmaceutical Enter Development and License Agreement for Multispecific Antibody C...

                            Details : Under the terms of the license agreement, Ono acquires intellectual property rights and exclusive global development and commercialization rights for a multispecific antibody targeting a novel immuno-oncology target.

                            Product Name : Undisclosed

                            Product Type : Large molecule

                            Upfront Cash : Undisclosed

                            March 31, 2022

                            Lead Product(s) : Antibody

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery Platform

                            Sponsor : Ono Pharmaceutical

                            Deal Size : $276.6 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Numab Therapeutics

                            Switzerland arrow
                            ELCC
                            Not Confirmed

                            Numab Therapeutics

                            Switzerland arrow
                            ELCC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ND021

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Recipient : Sunshine Guojian Pharmaceutical

                            Deal Size : $15.2 million

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Numab and 3SBio’s Sunshine Guojian Expand Partnership to Develop Novel T Cell Engager NM28

                            Details : Under the agreement, Sunshine Guojian has the right to select up to five antibody molecules including ND021, emerging from the three multispecific antibody programs based on Numab’s R&D platform and has the licenses to develop and commercialize each of...

                            Product Name : ND021

                            Product Type : Large molecule

                            Upfront Cash : Undisclosed

                            December 14, 2021

                            Lead Product(s) : ND021

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Recipient : Sunshine Guojian Pharmaceutical

                            Deal Size : $15.2 million

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Numab Therapeutics

                            Switzerland arrow
                            ELCC
                            Not Confirmed

                            Numab Therapeutics

                            Switzerland arrow
                            ELCC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NM21-1480

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Novo Holdings

                            Deal Size : $110.0 million

                            Deal Type : Series C Financing

                            DEALS_DEV arrow-down

                            Numab Therapeutics Completes Oversubscribed CHF 100 Million Series C Financing

                            Details : Proceeds will support acceleration and expansion of the clinical development of Numab’s lead program NM21-1480 into multiple cancer indications, and the advancement of the company’s pipeline of multi-specific antibodies in oncology and inflammation, ...

                            Product Name : NM21-1480

                            Product Type : Large molecule

                            Upfront Cash : Undisclosed

                            May 20, 2021

                            Lead Product(s) : NM21-1480

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Novo Holdings

                            Deal Size : $110.0 million

                            Deal Type : Series C Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth